Shire expands rare disease reach

Share this article:

Shire, which is soon to be AbbVie, has finalized a deal with US biotech ArmaGen. The $225-million deal gives Shire worldwide commercialization rights to the experimental enzyme replacement therapy AGT-182, which could be used to treat what the firms describe in a statement as “the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome.”

Hunter syndrome is a rare disease in which the body can't get rid of cellular waste. Around 1,200 patients have been diagnosed with the genetic disorder.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.